
Opinion|Videos|March 25, 2025
Pharmacist-Led Strategies for Adverse Event Management in mCRC
Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.
Advertisement
Video content above is prompted by the following:
- In what ways do pharmacists contribute to managing adverse events and toxicity for patients undergoing mCRC treatment?
- What factors influence patient adherence to third-line therapies for mCRC, and how can pharmacists improve patient education to address these challenges and ensure better adherence to treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
How Clinician-Led Partnerships Strengthen Post-Acute Care
4
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
5